Viva Vision Biotech

Wenzhou, China · Founded 2016 · In IPO Registration

Developer and manufacturer of innovative ophthalmology therapeutics and ophthalmic formulations designed for anterior and posterior segment eye diseases. Viva Vision Biotech is based in Wenzhou, China and was founded in 2016. Its last reported valuation was $257 million in Nov 2025. It has raised $107 million.

Last reported valuation
$256.6M
Oct 2026
Priced at
—
Total raised
$107.4M
Last round
—

Who backs Viva Vision Biotech?

26 investors
InvestorType
HSG (Hong Kong)Other
Guangdong Technology Financial GroupOther
Lapam CapitalVenture capital
V-CapitalVenture capital
Shenzhen GTJA Investment GroupOther
Viva BioInnovatorOther
Hunan Energy GroupOther
Shanghai Zhangjiang Torch Venture CapitalOther
JMCR Family OfficeFamily office
Betta Pharmaceuticals—
+ 16 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Viva Vision Biotech investors

26 investors are on record for Viva Vision Biotech, including HSG (Hong Kong), Guangdong Technology Financial Group, Lapam Capital and V-Capital.

Free account
More of Viva Vision Biotech with a free account
  • ·The complete investor list: 26 names
  • ·Watch Viva Vision Biotech: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 26 firms already write checks for companies like Viva Vision Biotech. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View